GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesit...

詳細記述

保存先:
書誌詳細
出版年:Cell Rep Med
主要な著者: Iepsen, Eva W., Have, Christian T., Veedfald, Simon, Madsbad, Sten, Holst, Jens J., Grarup, Niels, Pedersen, Oluf, Brandslund, Ivan, Holm, Jens-Christian, Hansen, Torben, Torekov, Signe S.
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2020
主題:
Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659505/
https://ncbi.nlm.nih.gov/pubmed/33205056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2020.100006
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料